Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation
- PMID: 29331941
- DOI: 10.1136/gutjnl-2017-315766
Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation
Keywords: Crohn’s disease; Inflammatory bowel disease; Pharmacokinetics; Ulcerative colitis; Vedolizumab.
Conflict of interest statement
Competing interests: CG, LP, HR, CZ and CB have nothing to disclose. LP-B received consulting fees from Merck, AbbVie, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillotts, Vifor, Pharmacosmos, BMS, UCB-Pharma, Hospira, Celltrion, Takeda, Biogaran, Boehringer-Ingelheim, Lilly, Pfizer, HAC-Pharma, Index Pharmaceuticals, Amgen, Sandoz, Forward Pharma GmbH, Celgene, Biogen, Lycera and Samsung Bioepis and received lecture fees from Merck, AbbVie, Takeda, Janssen, Ferring, Norgine, Tillotts, Vifor, Mitsubishi and HAC-Pharma.
Comment on
-
The safety of vedolizumab for ulcerative colitis and Crohn's disease.Gut. 2017 May;66(5):839-851. doi: 10.1136/gutjnl-2015-311079. Epub 2016 Feb 18. Gut. 2017. PMID: 26893500 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical